FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2980452345> ?p ?o ?g. }

• W2980452345 endingPage "e000535" @default.
• W2980452345 startingPage "e000535" @default.
• W2980452345 abstract "Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors have been established as effective treatment for metastatic renal cell carcinoma (mRCC), but only a minority of patients achieve complete response. Additional strategies are necessary to improve these agents' efficacy.Patients with stable disease for at least 4 months on TKI or checkpoint inhibitors were included. Stereotactic body radiotherapy (SBRT) was delivered to an organ with comparable lesions, where one lesion was in the treatment target and the other one was intentionally left untreated (control lesion). Response in both lesions was scored using the Response Evaluation Criteria in Solid Tumors V.1.1 criteria 2 months after completion of SBRT. The primary endpoint was the rate of SBRT adverse events, and the secondary endpoints included the rate of reduction in target lesion size.17 patients were enrolled (14 men and 3 women, median age: 54.5 years old). SBRT was delivered to the lungs (n=5), bones (n=4), lymph nodes (n=4), liver (n=1), primary renal cell carcinoma (RCC) (n=1) and locally recurrent RCC (n=2). The equivalent dose in 2 Gy with an alpha to beta ratio of 2.6 was 114 Gy. With a median follow-up of 8 months, the cumulative rate of SBRT-related toxicity (grade 1) was 12% (n=2), consisting of oesophagitis and skin erythema. No grade 2 or higher toxicity was detected. Radiographic response in the target lesion was seen in 13 patients (76%), with complete response in 5 (29%) patients and partial response in 8 (47%), including abscopal effect in 1 patient. Control lesions remained stable in 16 patients. The difference between response in the target and control lesions as judged by the mean sizes of these lesions before and at 2 months after SBRT was statistically significant (p<0.01). Fraction size of 10 Gy or greater was associated with complete response (p<0.01).Extracranial SBRT in patients with mRCC treated with TKI or checkpoint inhibitors is well tolerated and could be effective.NCT02864615." @default.
• W2980452345 created "2019-10-25" @default.
• W2980452345 creator A5006603624 @default.
• W2980452345 creator A5009521774 @default.
• W2980452345 creator A5016059034 @default.
• W2980452345 creator A5067503125 @default.
• W2980452345 creator A5070988170 @default.
• W2980452345 creator A5082076153 @default.
• W2980452345 date "2019-01-01" @default.
• W2980452345 modified "2023-10-13" @default.
• W2980452345 title "Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study" @default.
• W2980452345 cites W1789645352 @default.
• W2980452345 cites W2016177359 @default.
• W2980452345 cites W2021565823 @default.
• W2980452345 cites W2033092567 @default.
• W2980452345 cites W2038179631 @default.
• W2980452345 cites W2048195498 @default.
• W2980452345 cites W2057980517 @default.
• W2980452345 cites W2087671265 @default.
• W2980452345 cites W2115538252 @default.
• W2980452345 cites W2120058413 @default.
• W2980452345 cites W2222086386 @default.
• W2980452345 cites W2318044478 @default.
• W2980452345 cites W2335012284 @default.
• W2980452345 cites W2426671653 @default.
• W2980452345 cites W2523033537 @default.
• W2980452345 cites W2559911131 @default.
• W2980452345 cites W2624275086 @default.
• W2980452345 cites W2736209264 @default.
• W2980452345 cites W2745056454 @default.
• W2980452345 cites W765153079 @default.
• W2980452345 doi "https://doi.org/10.1136/esmoopen-2019-000535" @default.
• W2980452345 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6802957" @default.
• W2980452345 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31673426" @default.
• W2980452345 hasPublicationYear "2019" @default.
• W2980452345 type Work @default.
• W2980452345 sameAs 2980452345 @default.
• W2980452345 citedByCount "28" @default.
• W2980452345 countsByYear W29804523452020 @default.
• W2980452345 countsByYear W29804523452021 @default.
• W2980452345 countsByYear W29804523452022 @default.
• W2980452345 countsByYear W29804523452023 @default.
• W2980452345 crossrefType "journal-article" @default.
• W2980452345 hasAuthorship W2980452345A5006603624 @default.
• W2980452345 hasAuthorship W2980452345A5009521774 @default.
• W2980452345 hasAuthorship W2980452345A5016059034 @default.
• W2980452345 hasAuthorship W2980452345A5067503125 @default.
• W2980452345 hasAuthorship W2980452345A5070988170 @default.
• W2980452345 hasAuthorship W2980452345A5082076153 @default.
• W2980452345 hasBestOaLocation W29804523451 @default.
• W2980452345 hasConcept C121608353 @default.
• W2980452345 hasConcept C126322002 @default.
• W2980452345 hasConcept C126838900 @default.
• W2980452345 hasConcept C126894567 @default.
• W2980452345 hasConcept C141071460 @default.
• W2980452345 hasConcept C143998085 @default.
• W2980452345 hasConcept C197934379 @default.
• W2980452345 hasConcept C203092338 @default.
• W2980452345 hasConcept C2776694085 @default.
• W2980452345 hasConcept C2777472916 @default.
• W2980452345 hasConcept C2777546739 @default.
• W2980452345 hasConcept C2777701055 @default.
• W2980452345 hasConcept C2778822529 @default.
• W2980452345 hasConcept C2779984678 @default.
• W2980452345 hasConcept C2781156865 @default.
• W2980452345 hasConcept C2781274730 @default.
• W2980452345 hasConcept C29730261 @default.
• W2980452345 hasConcept C31760486 @default.
• W2980452345 hasConcept C509974204 @default.
• W2980452345 hasConcept C535046627 @default.
• W2980452345 hasConcept C71924100 @default.
• W2980452345 hasConceptScore W2980452345C121608353 @default.
• W2980452345 hasConceptScore W2980452345C126322002 @default.
• W2980452345 hasConceptScore W2980452345C126838900 @default.
• W2980452345 hasConceptScore W2980452345C126894567 @default.
• W2980452345 hasConceptScore W2980452345C141071460 @default.
• W2980452345 hasConceptScore W2980452345C143998085 @default.
• W2980452345 hasConceptScore W2980452345C197934379 @default.
• W2980452345 hasConceptScore W2980452345C203092338 @default.
• W2980452345 hasConceptScore W2980452345C2776694085 @default.
• W2980452345 hasConceptScore W2980452345C2777472916 @default.
• W2980452345 hasConceptScore W2980452345C2777546739 @default.
• W2980452345 hasConceptScore W2980452345C2777701055 @default.
• W2980452345 hasConceptScore W2980452345C2778822529 @default.
• W2980452345 hasConceptScore W2980452345C2779984678 @default.
• W2980452345 hasConceptScore W2980452345C2781156865 @default.
• W2980452345 hasConceptScore W2980452345C2781274730 @default.
• W2980452345 hasConceptScore W2980452345C29730261 @default.
• W2980452345 hasConceptScore W2980452345C31760486 @default.
• W2980452345 hasConceptScore W2980452345C509974204 @default.
• W2980452345 hasConceptScore W2980452345C535046627 @default.
• W2980452345 hasConceptScore W2980452345C71924100 @default.
• W2980452345 hasIssue "5" @default.
• W2980452345 hasLocation W29804523451 @default.
• W2980452345 hasLocation W29804523452 @default.
• W2980452345 hasLocation W29804523453 @default.
• W2980452345 hasLocation W29804523454 @default.
• W2980452345 hasOpenAccess W2980452345 @default.

• next